Modeling by the Joint United Nations Programme on HIV/AIDS (UNAIDS) indicates that there is a window of opportunity to end the human immunodeficiency virus (HIV)/AIDS epidemic by reaching the "90-90-90" targets, meaning that 90% of HIV infections are diagnosed, 90% of persons known to be HIV infected are receiving combination antiretroviral therapy (cART), and 90% of individuals receiving cART are virologically suppressed \[[@CIT0001], [@CIT0002]\]. In response, the World Health Organization (WHO) in its consolidated 2016 guidelines on the use of antiretroviral drugs for treating and preventing HIV infection recommended "lifelong cART to all children, adolescents and adults, including all pregnant and breastfeeding women living with HIV, regardless of CD4 cell count" \[[@CIT0003]\].

Many individuals who live with HIV continue to enter care late. A previous analysis of cART programs and HIV cohort studies from low-income countries (LICs), lower-middle-income countries (LMICs), upper-middle-income countries (UMICs), and high-income countries (HICs) showed that median CD4 cell counts at the start of cART increased from 2000 to 2009 but remained below 200/µL in LICs and middle-income countries (MICs) and below 300/µL in HICs \[[@CIT0004]\]. Similarly, a study published in *Morbidity and Mortality Weekly Report* \[[@CIT0005]\] found that the percentage of patients starting cART with a CD4 cell count below 200/µL had decreased in 10 LICs and MICs but continued to be substantial in recent years, for example, 37% in Mozambique in 2014, or 34% in Haiti in 2015 \[[@CIT0005]\]. A meta-analysis of African studies showed that the mean estimated CD4 cell count in 2012 was 309/µL at presentation to care and 140/µL at cART initiation \[[@CIT0006]\]. Similarly, a meta-regression analysis of studies in developed countries showed only a small increase in the CD4 cell count at presentation from 1992 to 2011 \[[@CIT0007]\].

For the present study, the International epidemiology Databases to Evaluate AIDS (IeDEA), a large collaboration of cART treatment programs and HIV cohort studies in the Americas, sub-Saharan Africa, and Asia-Pacific joined forces with the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) to examine global trends in CD4 cell counts at cART initiation.

METHODS {#s5}
=======

Data Sources {#s6}
------------

IeDEA is a consortium structured through regional centers to pool clinical and epidemiological data on persons living with HIV and receiving cART. COHERE is a collaboration of European HIV cohorts. Regional cohorts of IeDEA and COHERE have been described in detail elsewhere \[[@CIT0008]\]. Institutional review boards approved the pooling of data and their use in collaborative analyses.

Inclusion Criteria and Definitions {#s7}
----------------------------------

We included all individuals aged ≥16 years if they had a recorded cART starting date and sex, were treatment naive, and started therapy between 2002 and 2015. We excluded countries that contributed \<100 patients with CD4 cell counts at therapy start and individual patients who started therapy in a year and country for which \<10 CD4 cell counts were reported. cART was defined as ≥3 antiretroviral drugs, from 2 drug classes. The CD4 cell count at the start of cART was the count nearest to the date of starting cART, within a window of 3 months before and 1 week after initiation of therapy. CD4 cell counts \>5000/μL (\>3 times above the upper reference range \[[@CIT0013]\]) were considered invalid. Countries were grouped according to the World Bank classification of gross national income per capita in 2015 \[[@CIT0014]\], as LICs (≤\$1025), LMICs (\$1026--\$4035), UMICs (\$4036--\$12475), and HICs (≥\$12476). Severe immunodeficiency was defined as a CD4 cell count \<200/μL \[[@CIT0015]\]. Regions were defined according to IeDEA and COHERE conventions \[[@CIT0008], [@CIT0016]\].

Multiple Imputation of Missing CD4 Cell Counts {#s8}
----------------------------------------------

We imputed square roots of CD4 cell counts using predictive mean matching, adjusting for country and year of cART start and stratifying by sex, country income group, and region. We generated 50 imputed data sets and combined these using Rubin's rule \[[@CIT0017]\].

Weighted Analysis of Temporal Trends {#s9}
------------------------------------

We aggregated data by calendar year (3--14 years, depending on the country), country (55 countries), and sex (2 groups), and we calculated the median CD4 cell count at the start of cART for each of the resulting data cells. We assigned a weight to each data cell that consisted of 2 components, which were multiplied. The first component corresponded to the number of observations, divided by the average number of observations in data cells of the same country income group (and was thus normalized by country income group), and captured the precision of the aggregated values in each data cell. The second component corresponded to the ratio of the number of patients who were newly enrolled in that cohort and year to the number of patients starting cART in that country and year, as estimated by UNAIDS \[[@CIT0018]\] and was also normalized by country income group.

We used weighted additive mixed models to analyze temporal trends in median CD4 cell counts at the start of cART. The covariates sex and country income group, as well as their interaction, were included as fixed effects, country as a random intercept, and yearly trends smoothed by sex and country income group. Similarly, we analyzed the median CD4 cell count according to region instead of country income group. For this analysis, weights were normalized by region. We also modeled the proportion of patients starting cART with severe immunodeficiency (CD4 cell count \<200/µL), using generalized additive mixed models, and we fitted this model to other CD4 cell count thresholds (\<50/µL, \<100/µL, \<350/µL, and \<500/µL). We used the data set that included imputed CD4 cell counts. In sensitivity analyses, we fitted models to the data set consisting of complete cases only. We also fitted models including only cohorts that contributed data each year from 2005 to 2014.

We present CD4 cell counts as observed or modeled median CD4 cell counts with interquartile ranges (IQRs) or 95% confidence intervals (CIs). All analyses were done using R software, version 3.2.3 (R Core Team). The appendix gives further technical details (see [Supplementary Digital Content](#sup1){ref-type="supplementary-material"}).

RESULTS {#s10}
=======

Descriptive Analyses {#s11}
--------------------

We received data from 1472098 patients. We excluded a total of 520243 patients and 22 countries who did not meet the inclusion criteria. [Supplementary Figure S1](#sup1){ref-type="supplementary-material"} (see [Supplementary Digital Content](#sup1){ref-type="supplementary-material"}) shows the inclusion of patients. A total of 951 855 individuals from 55 countries (16 LICs, 11 LMICs, 9 UMICs, and 19 HICs) were included ([Table 1](#T1){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}). Five countries contributed 160--499 persons; 6 countries, 500--999; 20 countries, 1000--4999; 5 countries, 5000--9999; 12 countries, 10000--24999; and 7 countries, ≥25000. The number of individuals included in each country ranged from 160 (Malaysia) to 350595 (Zambia).

###### 

Characteristics of Persons Living With Human Immunodeficiency Virus Starting Combination Antiretroviral Therapy by World Bank Income Group (2015), Country, and Sex

  Country by Income Status            Patients, No.   Age, Median, y   Calendar Year of cART Initiation, Median   Range of Data, Calendar Years                                           
  ----------------------------------- --------------- ---------------- ------------------------------------------ ------------------------------- ------------------- ------------------- ------------
  Low income                                                                                                                                                                              
   Benin                              2542            1559             33                                         40                              2009                2008                2002--2014
   Burkina Faso                       7832            3312             35                                         41                              2008                2008                2002--2014
   Burundi                            3123            1711             35                                         43                              2012                2012                2009--2015
   Democratic Republic of the Congo   1425            303              33                                         41                              2011                2011                2005--2014
   Guinea                             640             323              32                                         41                              2012                2012                2008--2014
   Guinea-Bissau                      1941            1002             35                                         40                              2010                2010                2007--2014
   Haiti                              3422            2287             34                                         40                              2013                2013                2003--2015
   Malawi                             29 965          20 219           31                                         37                              2011                2011                2007--2015
   Mali                               3222            1800             33                                         41                              2009                2009                2002--2014
   Mozambique                         6314            2925             29                                         36                              2013                2013                2006--2015
   Rwanda                             7730            4443             32                                         38                              2008                2008                2004--2015
   Senegal                            603             407              37                                         43                              2009                2009                2002--2014
   United Republic of Tanzania        8798            3999             36                                         41                              2009                2009                2005--2014
   Togo                               2649            1351             33                                         40                              2009                2009                2005--2009
   Uganda                             27 644          15 841           32                                         37                              2009                2009                2003--2014
   Zimbabwe                           15 652          7195             36                                         40                              2012                2012                2004--2015
   Overall (IQR)^a^                   123 502         68 677           33 (28--40)                                38 (32--45)                     2011 (2008--2013)   2010 (2008--2012)   2002--2015
  Lower middle income                                                                                                                                                                     
   Cambodia                           1136            1003             33                                         36                              2009                2009                2005--2014
   Cote d'Ivoire                      14 819          7725             35                                         42                              2008                2008                2002--2014
   Honduras                           436             562              33                                         38                              2006                2007                2002--2015
   India                              2802            6100             33                                         36                              2009                2008                2002--2014
   Kenya                              72 329          33 311           33                                         39                              2010                2010                2003--2014
   Lesotho                            6870            3638             35                                         40                              2011                2011                2005--2015
   Nigeria                            14 729          7587             32                                         39                              2008                2008                2005--2014
   Philippines                        16              191              36                                         30                              2010                2009                2008--2010
   Ukraine                            570             264              29                                         34                              2008                2009                2004--2014
   Vietnam                            554             918              30                                         34                              2012                2012                2004--2014
   Zambia                             217 525         133 070          33                                         37                              2011                2011                2003--2015
   Overall (IQR)^a^                   331 786         194 369          33 (28--40)                                38 (32--44)                     2010 (2008--2013)   2010 (2007--2013)   2002--2015
  Upper middle income                                                                                                                                                                     
   Argentina                          888             2161             35                                         37                              2008                2009                2002--2015
   Belarus                            235             258              32                                         34                              2009                2008                2006--2013
   Brazil                             774             1941             38                                         35                              2010                2010                2002--2015
   Malaysia                           31              129              37                                         37                              2008                2009                2004--2010
   Mexico                             104             858              35                                         33                              2009                2009                2002--2015
   Peru                               872             2328             34                                         33                              2010                2011                2004--2015
   Russian Federation                 159             159              29                                         32                              2008                2008                2003--2012
   South Africa                       45 359          24 240           33                                         38                              2010                2010                2003--2015
   Thailand                           451             586              36                                         37                              2008                2008                2003--2010
   Overall (IQR)^a^                   48 873          32 660           33 (28--40)                                37 (32--44)                     2010 (2007--2012)   2010 (2007--2012)   2002--2015
  High income                                                                                                                                                                             
   Austria                            627             1774             33                                         38                              2008                2010                2002--2014
   Belgium                            1205            1303             31                                         39                              2007                2010                2002--2014
   Canada                             295             818              36                                         39                              2008                2009                2003--2013
   Chile                              160             1415             37                                         35                              2006                2009                2002--2014
   Denmark                            609             1313             35                                         42                              2007                2008                2002--2013
   France                             9036            18 094           35                                         40                              2006                2007                2002--2014
   Germany                            2709            10 686           34                                         40                              2008                2009                2002--2015
   Greece                             555             2997             36                                         36                              2008                2010                2002--2014
   Hong Kong                          133             574              36                                         41                              2009                2010                2003--2013
   Italy                              3631            10 627           37                                         40                              2009                2009                2002--2015
   Republic of Korea                  18              364              41                                         37                              2011                2010                2002--2015
   Netherlands                        2806            11 078           33                                         41                              2008                2009                2002--2015
   Poland                             142             427              31                                         33                              2007                2008                2002--2013
   Singapore                          117             1643             41                                         42                              2010                2010                2006--2014
   Spain                              2218            9006             36                                         37                              2008                2009                2002--2014
   Sweden                             2138            3095             33                                         41                              2009                2009                2002--2015
   Switzerland                        882             2881             36                                         40                              2008                2009                2002--2014
   United Kingdom                     5823            13 976           35                                         38                              2007                2008                2002--2013
   United States                      4187            22 626           42                                         44                              2008                2008                2003--2014
   Overall (IQR)^a^                   37 291          114 697          35 (29--43)                                40 (33--48)                     2007 (2005--2010)   2008 (2006--2011)   2002--2015

Abbreviations: IQR, interquartile range.

^a^IQRs provided for median values.

![Map of countries contributing patients to the collaborative analysis by number of patients (*A*) and country income group (*B*).](cix91501){#F1}

The percentage of women was 57% overall and ranged from 5% in South Korea to 82% in the Democratic Republic of the Congo. In LICs, LMICs, and UMICs, the median (IQR) age of individuals starting cART was 35 (29--42) years; in HICs, it was 39 (32--47) years. The median year of cART initiation ranged from 2007 in France and Honduras to 2013 in Haiti and Mozambique. The median CD4 cell count at cART initiation ranged from 106/µL in Senegal, Thailand, and Vietnam to 275/µL in Belgium, and it was 182/μL overall; it was 179/μL (IQR, 85--288/μL) in LICs, 172/μL (85--279/μL) in LMICs, 141/μL (60--227/μL) in UMICs, and 251/μL (128--370/μL) in HICs. The proportion of patients starting cART with severe immunodeficiency (CD4 cell count \<200/µL) was 55%, ranging from 31% in Switzerland to 77% in Senegal; this proportion was 56% in LICs, 58% in LMICs, 68% in UMICs, and 38% in HICs. [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} and [Supplementary Table S3](#sup1){ref-type="supplementary-material"} show detailed results by country and sex.

###### 

Median CD4 Cell Count and Proportion of Persons Living With Human Immunodeficiency Virus Starting Combination Antiretroviral Therapy With Severe Immunodeficiency in 2002--2015 by World Bank Income Group (2015), Country, and Patient Sex

  Country by Income Status            Proportion of Patients Missing CD4 cell Count Measurements, %   CD4 Cell Count at cART Initiation, Median, Cells/µL   Proportion Starting cART With CD4 Cell Count \<200/µL, %                                                                     
  ----------------------------------- --------------------------------------------------------------- ----------------------------------------------------- ---------------------------------------------------------- ---------------- ---------------- ---------------- ---- ---- ---- ----
  Low income                                                                                                                                                                                                                                                                             
   Benin                              35                                                              35                                                    153                                                        97               155              100              63   77   62   76
   Burkina Faso                       37                                                              37                                                    212                                                        159              211              163              47   58   47   57
   Burundi                            64                                                              63                                                    252                                                        233              263              242              34   41   33   40
   Democratic Republic of the Congo   16                                                              20                                                    237                                                        198              241              200              41   51   41   50
   Guinea                             38                                                              42                                                    196                                                        167              195              167              51   58   51   59
   Guinea-Bissau                      21                                                              18                                                    164                                                        153              162              153              60   64   61   64
   Haiti                              31                                                              31                                                    267                                                        213              269              211              35   48   35   48
   Malawi                             71                                                              64                                                    187                                                        154              196              157              54   63   51   62
   Mali                               23                                                              22                                                    165                                                        119              165              119              56   70   57   70
   Mozambique                         38                                                              23                                                    270                                                        214              275              214              35   47   34   47
   Rwanda                             21                                                              22                                                    246                                                        198              246              198              39   50   39   51
   Senegal                            44                                                              42                                                    109                                                        101              112              106              75   80   74   79
   United Republic of Tanzania        34                                                              33                                                    126                                                        113              130              115              72   75   71   74
   Togo                               95                                                              94                                                    154                                                        150              144              156              71   72   69   63
   Uganda                             37                                                              34                                                    176                                                        146              172              138              57   65   58   67
   Zimbabwe                           31                                                              29                                                    197                                                        149              208              154              51   65   48   63
   Overall (IQR)^a^                   44                                                              43                                                    192 (97--303)                                              156 (68--258)    193 (98--304)    156 (68--255)    52   62   52   62
  Lower middle income                                                                                                                                                                                                                                                                    
   Cambodia                           6                                                               6                                                     178                                                        115              179              115              57   68   56   68
   Cote d'Ivoire                      36                                                              40                                                    176                                                        144              172              142              57   64   58   65
   Honduras                           22                                                              19                                                    120                                                        110              123              110              77   74   77   74
   India                              11                                                              9                                                     166                                                        122              167              122              64   74   63   74
   Kenya                              36                                                              32                                                    177                                                        120              182              124              57   73   55   71
   Lesotho                            20                                                              19                                                    226                                                        169              234              173              44   57   42   56
   Nigeria                            27                                                              26                                                    203                                                        152              205              154              49   62   49   61
   Philippines                        12                                                              3                                                     204                                                        192              209              192              50   52   48   52
   Ukraine                            34                                                              58                                                    246                                                        200              240              199              34   49   36   51
   Vietnam                            13                                                              9                                                     170                                                        70               168              71               59   77   60   78
   Zambia                             35                                                              31                                                    188                                                        158              195              161              54   62   51   61
   Overall (IQR)^a^                   34                                                              30                                                    186 (97--297)                                              149 (70--248)    191 (100--307)   152 (71--255)    54   64   52   63
  Upper middle income                                                                                                                                                                                                                                                                    
   Argentina                          35                                                              33                                                    209                                                        196              208              193              48   51   48   51
   Belarus                            28                                                              26                                                    196                                                        171              196              185              52   57   53   55
   Brazil                             17                                                              16                                                    239                                                        227              236              226              41   45   42   45
   Malaysia                           13                                                              19                                                    175                                                        151              175              151              59   64   58   64
   Mexico                             22                                                              12                                                    131                                                        160              132              160              67   59   66   59
   Peru                               24                                                              18                                                    145                                                        113              151              113              60   68   60   68
   Russian Federation                 50                                                              43                                                    209                                                        196              211              196              44   52   43   51
   South Africa                       28                                                              27                                                    149                                                        114              154              116              67   76   65   75
   Thailand                           10                                                              11                                                    123                                                        97               125              99               75   75   73   75
   Overall (IQR)^a^                   28                                                              26                                                    151 (70--232)                                              123 (48--218)    156 (72--242)    125 (49--220)    66   71   64   70
  High income                                                                                                                                                                                                                                                                            
   Austria                            15                                                              17                                                    237                                                        266              236              264              40   35   40   35
   Belgium                            36                                                              32                                                    266                                                        280              265              280              34   30   35   29
   Canada                             18                                                              17                                                    224                                                        238              227              243              43   38   42   37
   Chile                              29                                                              29                                                    201                                                        191              191              181              48   52   53   54
   Denmark                            29                                                              30                                                    231                                                        234              232              238              39   40   38   39
   France                             18                                                              17                                                    249                                                        266              250              266              36   35   36   35
   Germany                            29                                                              26                                                    223                                                        237              220              235              43   41   44   42
   Greece                             20                                                              22                                                    192                                                        249              192              249              52   38   51   38
   Hong Kong                          1                                                               2                                                     112                                                        111              109              111              70   66   70   66
   Italy                              27                                                              27                                                    252                                                        258              254              257              39   39   38   39
   Republic of Korea                  6                                                               4                                                     207                                                        221              207              221              47   44   47   44
   Netherlands                        28                                                              25                                                    230                                                        260              230              260              42   35   42   35
   Poland                             55                                                              51                                                    203                                                        238              217              228              50   39   48   41
   Singapore                          9                                                               9                                                     138                                                        128              134              133              62   62   62   61
   Spain                              19                                                              18                                                    229                                                        260              229              260              43   36   43   36
   Sweden                             29                                                              27                                                    230                                                        240              225              240              43   38   43   39
   Switzerland                        16                                                              13                                                    259                                                        270              259              270              34   30   34   30
   United Kingdom                     34                                                              34                                                    220                                                        245              220              244              44   37   44   37
   United States                      14                                                              14                                                    274                                                        272              276              273              36   37   36   36
   Overall (IQR)^a^                   24                                                              22                                                    241 (128--360)                                             254 (128--372)   240 (128--360)   253 (130--370)   40   37   40   37

Abbreviations: IQR, interquartile range.

^a^IQRs provided for median values.

Multiple Imputation of Missing CD4 Cell Counts {#s12}
----------------------------------------------

The CD4 cell count measurement at the start of cART was missing in 311647 patients, in 44% of individuals in LICs, 33% in LMICs, 27% in UMICs, and 22% in HICs ([Table 2](#T2){ref-type="table"}). Compared with them, the 640208 individuals who had a CD4 cell count reported at the start of cART were more likely to be female and less likely to be from a LIC ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Five countries from Southern Africa provided information about the WHO stage of patients at cART initiation. The WHO stage distributions were similar overall in patients with and those without reported CD4 cell counts ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}).

Medians of imputed CD4 cell counts from the main analysis and the complete cases (sensitivity analysis) were similar ([Table 2](#T2){ref-type="table"} and [Supplementary Table S3](#sup1){ref-type="supplementary-material"}). Differences in CD4 cell counts ranged from −10/μL in Ukraine to +10.5/μL in Burundi. Similarly, the proportion of patients starting cART with counts \<200/μL were similar for imputed and complete data. The differences ranged from −4.7% in Togo to +3.4% in Ukraine.

Temporal Trends in CD4 Cell Counts {#s13}
----------------------------------

The estimated median CD4 cell count at the start of cART from 2002 to 2015 varied across income groups ([Figure 2](#F2){ref-type="fig"}). The modeled median CD4 cell count at cART initiation increased in LICs by 268%, from 78/µL (95% CI, 58--104/µL) to 287/µL (250--328/µL); in LMICs by 136%, from 99/µL (71--140/µL) to 234/µL (192--285/µL); in UMICs by 338%, from 71/µL (49--104/µL) to 311/µL (255--379/µL); and in HICs by 103%, from 161/µL (143--181/µL) to 327/µL (286--372/µL). In LICs, LMICs, and UMICs the increase was more pronounced in women (+277% in LICs, +153% in LMICs, and +391% in UMICs) than in men (+248% in LICs, +99% in LMICs, and +261% in UMICs); in HICs the opposite was the case (+68% in women and +115% in men). Results of the complete case analysis and analysis restricted to cohorts contributing data from 2005--2014 were similar ([Supplementary Figure S2*A*](#sup1){ref-type="supplementary-material"} and [S2*B*](#sup1){ref-type="supplementary-material"}, [Supplementary Digital Content](#sup1){ref-type="supplementary-material"}).

![Median CD4 cell count in adults at the start of combination antiretroviral therapy (cART) by sex and country income group. Results from additive mixed-effects model based on 951855 adults after imputation of missing data. 95% confidence intervals are shown as shaded areas.](cix91502){#F2}

[Figure 3](#F3){ref-type="fig"} shows modeled temporal trends in the proportion of patients starting cART with severe immunodeficiency (CD4 cell count \<200/µL) and below other thresholds. In LICs, the estimated proportion of adults starting with severe immunodeficiency declined from 95% (95% CI, 90%--97%) in 2002 to 31% (26%--36%) in 2015. Corresponding declines were from 75% (95% CI, 65%--83%) to 40% (33%--47%) in LMICs, from 79% (71%--86%) to 26% (20%--33%) in UMICs, and from 59% (54%--64%) to 29% (24%--34%) in HICs. For the lowest 3 CD4 thresholds (\<50/µL, \<100/µL, and \<200/µL) the proportions of patients starting cART below the threshold declined over the study-period. However, trends plateaued toward the end of the study period, for example, for individuals from HICs or LMICs who started therapy with CD4 cell counts below 100/µL or 200/µL. The proportions for the 2 highest CD4 thresholds (\<350/µL and \<500/µL) were constant over the first few years and then started to decrease. Results of the complete case analysis and analysis restricted to cohorts contributing data from 2005--2014 were similar (see [Figure S3*A*](#sup1){ref-type="supplementary-material"} and [S3B](#sup1){ref-type="supplementary-material"}, [Supplementary Digital Content](#sup1){ref-type="supplementary-material"}).

![Proportion of patients starting combination antiretroviral therapy (cART) with CD4 cell counts below 50/µL, 100/µL, 200/µL, 350/µL, and 500/µL (rows) by sex (columns) and country income group (colors). Results from generalized additive mixed effects models based on 951855 adults after imputation of missing data. 95% confidence intervals are shown as shaded areas.](cix91503){#F3}

[Supplementary Figure S4](#sup1){ref-type="supplementary-material"} shows the modeled temporal trends in median CD4 cell count at the start of cART by sex and region. Regions showed different trends, with the largest increases in median CD4 cell count at the start of cART from 2003 to 2014 seen in Southern Africa (from 93/µL \[95% CI, 60--146/µL\] to 259/µL \[224--300/µL\]) and North America (from 172/µL \[131--227/µL\] to 435/µL \[317--597/µL\]) and the smallest increases seen in West Africa (from 118/µL \[88--158/µL\] to 186/µL \[160--217/µL\]) and East Europe (from 160/µL \[101--254/µL\] to 261/µL \[199--342/µL\]). Results from complete case analysis and analysis restricted to cohorts contributing data from 2005--2014 were similar (see [Supplementary Figure S4A](#sup1){ref-type="supplementary-material"} and [S4B](#sup1){ref-type="supplementary-material"}, [Supplementary Digital Content](#sup1){ref-type="supplementary-material"}).

DISCUSSION {#s14}
==========

This global analysis of the CD4 cell count at cART initiation included almost 1 million individuals living with HIV in North America, Latin America and the Caribbean, Asia-Pacific, sub-Saharan Africa, and Europe. The median CD4 cell count substantially increased in all 4 groups of countries defined by per capita income, with steeper increases in LICs and UMICs than in LMICs or HICs. In 2015, these counts were highest in HICs, followed by UMICs, LICs, and LMICs. There were also important differences between regions. For example, the estimated median CD4 cell count in individuals starting cART in North America rose to 435/µL in 2014; at the other end of the spectrum, it was 186/µL in individuals starting cART in West Africa in the same year. Median CD4 cell counts were higher and increases steeper in women than in men, except in HICs, where in recent years women started cART with lower counts than men. The proportion starting therapy with severe immunodeficiency decreased substantially, but trends seemed to have plateaued in recent years, especially in HICs.

The decreases in the proportion of patients starting therapy below the different CD4 thresholds mirror the WHO guidelines to some extent. For example, the proportion starting with a CD4 cell count below 350/µL was close to 100% in LICs, LMICs, and UMICs until about 2010, and started declining after that point, possibly owing to the implementation of the 2009 guideline \[[@CIT0019]\]. In HICs the decline had already started before the guideline expansion, in 2008. This reflects the fact that national guidelines in resource-limited settings generally echoed WHO guidelines \[[@CIT0020]\], whereas HICs have more rapidly increased the CD4 cell count threshold for initiation of cART. For example, in 2012 North American guidelines converged in their recommendation that cART should be offered to all HIV-infected individuals, irrespective of CD4 cell count \[[@CIT0021], [@CIT0022]\]. The WHO followed suit in 2016, recommending "lifelong cART for all children, adolescents and adults, including all pregnant and breastfeeding women living with HIV, regardless of CD4 cell count" \[[@CIT0003]\]. The impact of these recommendations will be the subject of future collaborative analyses.

It is likely that the substantial rise in HIV testing in many countries, supported by governments, the US President's Emergency Plan for AIDS Relief (PEPFAR), the Global Fund, and other donors contributed to increasing CD4 cell counts at the start of cART \[[@CIT0023]\], but this may not have been the case in all settings \[[@CIT0024], [@CIT0025]\]. The steeper increase in CD4 cell count among women compared with men in LICs and MICs may be explained by increased testing coverage after scale-up of programs to prevent mother-to-child transmission. UNAIDS estimates that 90% of pregnant women living with HIV in Eastern and Southern Africa, 48% in Central and West Africa and 41% in Asia and the Pacific received antiretroviral drugs \[[@CIT0026]\], up from \<5% in 2002 \[[@CIT0027]\]. However, among the 22 UNAIDS priority countries \[[@CIT0028]\], several still had coverage rates below 50% in 2015 for programs to prevent mother-to-child transmission, including India, Chad and Nigeria \[[@CIT0026]\].

Analyses were based on raw data from many HIV-infected individuals starting cART, which is an important strength of this study. Such individual patient data meta-analyses have been described as the "yardsticks" against which the quality of other reviews should be judged \[[@CIT0029]\]. Our results are consistent with an earlier analysis of IeDEA and European data, based on individual patient data from 379865 patients in 23 countries, which showed that CD4 cell counts in LICs and MICs increased from about 90/µL in 2002 to about 150/µL in 2009 \[[@CIT0004]\]. Our results are also in line with analyses of individual patient data from a smaller number of countries \[[@CIT0005], [@CIT0030], [@CIT0031]\].

The weighting of estimates was another strength, with more weight given to the more precise estimates of median CD4 cell count, and by the number of patients starting cART in a given country and year \[[@CIT0018]\], so that countries with many patients starting cART were adequately represented in our analysis. Our study also had several limitations. We included data up to 2015, but not all countries contributed data spanning the entire period from 2002 to 2015. It is reassuring that results were very similar when we restricted analyses to the cohorts that contributed data for each year from 2005 to 2014.

Another limitation was that many individuals had missing CD4 cell counts at cART initiation, which we addressed by multiple imputation. Results including the imputed values were very similar to those of complete case analyses. If some of the CD4 cell counts were missing owing to poorer health, this would violate the assumption of values missing at random and lead to overestimation of the median count. For example, some patients with missing CD4 cell counts may have started therapy immediately because of an opportunistic infection and might thus be more likely to have a lower count, especially in LICs. Data on opportunistic infections and clinical stage was incomplete, and we could not use this information in our imputation models. However, for the 5 Southern African countries, which provided information on clinical stage, the WHO stage distribution overall was similar in patients with reported and those with missing CD4 cell counts. These data indicate that, at least in Southern Africa, only a small portion of missing counts are due to poorer health.

Data from some countries were limited to a small number of patients from a single clinic. We excluded these data sets because the data were probably unrepresentative of all patients receiving cART in those countries. Some data included in modeling of time trends may also not be representative of all patients receiving cART in the country. In particular, the clinics from LICs and MICs participating in IeDEA are mainly urban and capture data in electronic databases, indicating a higher level of resources. They may more closely reflect best practice in urban settings than in the country as a whole \[[@CIT0008]\]. Nevertheless, our collaborative study is a unique source of information on trends and determinants of the CD4 cell count in adult patients starting cART across the globe.

In conclusion, median CD4 cell counts at the start of cART have increased in all country income groups over the last few years, and the proportion of individuals starting cART with severe immunodeficiency has decreased. However, the median CD4 cell count at cART start generally remained below 350/μL in 2015 and the decline in severe immunodeficiency appears to have plateaued in some countries. Clearly, substantial additional efforts and resources will be needed to achieve early diagnosis, rapid linkage to care, and prompt initiation of cART globally.
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